FPT Software and uniqbit Partner to Accelerate Digital Transformation in Energy and Retail
7.10.2024 10:28:00 CEST | Business Wire | Press release
Global leading IT company FPT Software, a subsidiary of FPT Corporation (FPT), and German IT consulting company specializing in customized digital solutions—uniqbit AG recently entered a strategic partnership to foster innovation and business development across Germany and the wider European region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241006502822/en/
(Graphic: Business Wire)
The strategic partnership between FPT Software and uniqbit AG focuses on advancing digital transformation by developing innovative platforms for companies in the energy and retail sectors. This is expected to address the growing demand for digital solutions that enhance efficiency and sustainability while allowing both sides to expand their market presence.
uniqbit offers customized digital platforms designed to meet unique business needs, with a track record in accompanying German industry giants. Leveraging uniqbit's industry expertise and robust local network in the energy and retail sectors, FPT Software will further expand existing operations in German and European markets while enhancing its service offerings in retail and energy industries. Meanwhile, uniqbit can also tap into FPT Software’s extensive global network and technological capabilities to expand its solutions to a wider range of customers in these sectors.
Tran Van Dzung, Chief Executive Officer of FPT Software Europe said: “Retail and energy are among Germany's core sectors and also areas where FPT Software has extensive experience. With this partnership, we hope to combine our global expertise with uniqbit’s local knowledge and specialized solutions to deliver impactful digital services across these industries and empower our clients to navigate their digital transformation.”
“This formal partnership with FPT represents an opportunity for both companies to accelerate our growth and innovation efforts. Together, we will leverage our complementary strengths to develop advanced digital platforms that deliver meaningful value to our clients and support long-term business objectives,” shared Tom Weber, uniqbit AG’s founder.
FPT entered the European market in 2008 and has since become a trusted partner in digital transformation, providing end-to-end services and innovative solutions to more than 150 European leading companies across industries, such as E.ON, Schaeffler, Viessmann, Covestro, Volvo, and Siemens. The company currently has a presence in nine countries, with recent office openings in Nuremberg, Germany, and Gothenburg, Sweden. To meet the increasing demand for digital solutions and services in this region, FPT aims to expand its workforce to 1,000 IT professionals, with 50% of roles being filled by local talent by 2030.
About FPT Software
FPT Software, a subsidiary of FPT Corporation, is a global technology and IT services provider headquartered in Vietnam, with $1 billion in revenue (2023) and over 30,000 employees in 30 countries.
The company champions complex business opportunities and challenges with its world-class services in Advanced Analytics, AI, Digital Platforms, Cloud, Hyperautomation, IoT, Low-code, and so on. It has partnered with over 1,100 clients worldwide, nearly 100 of which are Fortune Global 500 companies in Aviation, Automotive, Banking, Financial Services and Insurance, Healthcare, Logistics, Manufacturing, Utilities, and more. For more information, please visit https://fptsoftware.com/
About uniqbit
uniqbit AG is a software & consulting company based in Augsburg, Bavaria, Germany which focuses on retail, energy and the public sector. With 50+ employees, uniqbit is an IT frontrunner company which supports Germany's top companies in custom made IT projects. As an innovative technology consultancy & implementation partner, uniqbit focuses on delivering customized digital solutions for clients across various industries. With a strong presence in the energy and retail sectors, uniqbit has built a reputation for providing tailored platforms that meet specific client needs, including for major clients like E.ON Energie Deutschland and REWE Digital.
Besides providing the highest level of quality for the customers, uniqbit has a very strong focus on developing local talents in collaboration with multiple universities and has been awarded the top company award three years in a row now. For more information, please visit https://uniqbit.de
View source version on businesswire.com: https://www.businesswire.com/news/home/20241006502822/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom